Connect with us

Technology

Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board

Published

on

Dr Hoekema brings over four decades of successful biotech and life science leadershipDr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COONew hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships

SOUTHAMPTON, England, Oct. 2, 2024 /PRNewswire/ — Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the further strengthening of its leadership team with the appointments of Andre Hoekema as Chair of the Board and Cora Griffin as Head of Business Development. The appointments continue the strong momentum at Curve following the recent appointment of Simon Jones as CFO/COO.

Dr Hoekema is a highly experienced and successful biotech executive with 40 years’ experience in the industry. He served as Chief Business Officer and member of the Executive Committee at Galapagos Pharma for 18 years, with responsibility spanning M&A, business development and IP. During his time at Galapagos, he led multiple pharma partnerships, acquisitions and divestments, including two landmark deals with Gilead. He was also part of the team that completed successful IPOs on Euronext (2005) and Nasdaq (2015). Andre serves as a member of the supervisory advisory boards of Artax Biopharma, Fibrocor Therapeutics and Mimetas BV.

Curve has also appointed Cora Griffin, an accomplished life sciences business development professional and entrepreneur, as Head of Business Development. Dr Griffin has considerable experience in developing and implementing portfolio strategies from start-ups to large pharmaceutical companies. She was previously Head of Business Development & Alliance Management at ReViral and was instrumental in the acquisition by Pfizer for US$525 million. Cora served as Anti-infectives Strategy Lead at Pfizer, responsible for the Infectious Diseases portfolio strategy for the Research Unit. She is a Jury Member for the EIC Accelerator program for the European Innovation Council and Board Observer at Oppilotech.

Simon Kerry, Chief Executive Officer of Curve Therapeutics, said: “Following the significant Series A financing, we are building a world-class leadership team to turbocharge our proprietary discovery platform and rapidly progress our pipeline. Andre’s wealth of experience in the sector and significant track record, and Cora’s visionary outlook and strategic nous, will be invaluable as we grow the business and progress our lead candidate towards the clinic. We are well placed to accelerate our ambition to build out the pipeline and work with strategic partners to address complex and challenging disease targets and improve patient outcomes.”

Andre Hoekema, PhD, new Chair of Curve Therapeutics, commented: “Curve is an ambitious and innovative biotech with the mission to revolutionize the drug discovery space with its Microcycle discovery platform. Through its pioneering and truly unique approach, Curve is building an innovative therapeutic pipeline and establishing strong relationships with major pharma. I look forward to working with Simon and the leadership team to help the Company progress to the next stage of growth.”

About Curve Therapeutics 

Curve Therapeutics is a private biotechnology company pioneering a revolutionary intracellular screening platform to enable the discovery of innovative therapeutics that address complex and challenging disease targets with the potential to transform the lives of patients. Curve originated from world-leading Microcycle research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. Curve is backed by blue chip investors including Advent Life Sciences, Epidarex Capital, Pfizer Ventures, Columbus Venture Partners and British Patient Capital. Curve has a US$1.7bn global research collaboration with MSD the trade name of Merck & Co., Inc., Kenilworth, NJ USA, to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications. For more information visit: www.curvetx.com.

About Curve’s Microcycle platform

Curve has developed an IP-protected, mammalian cell platform technology, for functional screening and enrichment of diverse hexameric cyclic peptide Microcycle libraries, to identify those library members that have the desired biological activity against a therapeutic target. Curve’s platform allows direct screening for biologically active library members inside mammalian cells and facilitates small molecule hit-to-lead programs. A key advantage of the technology is that both the library and the target are present in all their native conformations within a cell. Uniquely, the compact size and rigid structure of Microcycles enables the design of non-peptide small molecule leads. The disease agnostic discovery platform can be used for a wide range of therapeutically relevant targets, including protein-protein and protein-DNA interactions, and has been used by Curve to develop a pipeline of cancer programs against targets including a dual HIF-1/HIF-2 inhibitor and an inhibitor of ATIC homodimerization.

View original content:https://www.prnewswire.co.uk/news-releases/curve-therapeutics-further-strengthens-leadership-team-with-the-appointment-of-andre-hoekema-as-new-chair-of-board-302264539.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Chicago-Based Fintech App SHENIX® Celebrates First Anniversary On Latina Equal Pay Day Oct. 3; Platform founder describes new app features, way to close Latina wage gap

Published

on

By

October 3 denotes a special milestone for SHENIX®, powered by FARO Advisory, a groundbreaking leading educational fintech platform designed specifically for Latinas, which is marking the first anniversary of its launch. The free app, available on Apple’s IOS and Google Play stores, empowers Latinas and anyone who identifies with this group to make informed financial decisions for themselves, their families, careers, businesses, and communities.

CHICAGO, Oct. 2, 2024 /PRNewswire-PRWeb/ — October 3 denotes a special milestone for SHENIX®, powered by FARO Advisory, a groundbreaking leading educational fintech platform designed specifically for Latinas, which is marking the first anniversary of its launch. The free app, available on Apple’s IOS and Google Play stores, empowers Latinas and anyone who identifies with this group to make informed financial decisions for themselves, their families, careers, businesses, and communities.

“This Hispanic Heritage Month and Latina Equal Pay Day, SHENIX® is proud to share its new app updates that will help Latinas, and anyone get closer to reaching their financial goals.”

The anniversary also falls on Latina Equal Pay Day, which addresses the wage gap between Latinas and their peers. Part of SHENIX®’s mission is to not only help Latinas with their finances but also support them as they close the wealth divide.

Olga Camargo, CEO and founder of the Chicago-based SHENIX®, is excited to announce the new updated app features, which include financial planning software, opening brokerage accounts, investing advice, and access to career leadership programs.

“This Hispanic Heritage Month and Latina Equal Pay Day, SHENIX® is proud to share its new app updates that will help Latinas, and anyone get closer to reaching their financial goals,” she said. “All registered users can now access free financial planning software that will allow them and their family members to know more about their money and how to better plan these funds for financial goals like education, business, wealth building, and retirement. The app also allows U.S. Latinas and family members living in the U.S. to open brokerage accounts using their social security number or Individual Tax Identification Number (ITIN) IRA, Roth, IRA, Solo 401k, SEP IRA accounts for personal and small business needs. As always, users have access to career coaches and English and Spanish-speaking financial advisors.”

Camargo and other Latina business owners still see more work needs to be done to reach wage parity for Hispanic women. According to AAUW, “Latinas working full-time, year-round were paid 57 cents for every dollar paid to non-Hispanic white men in 2022, which increased to 58 cents in 2023. All earners, which also includes part-time and seasonal, were paid 52 cents for every dollar paid to non-Hispanic white men in 2022, which decreased to 51 cents in 2023.”

However, some statistics notice much growth in Latino/a entrepreneurs. The Latino Donor Collaborative, a 501(c)(3) Beverly Hills-based nonprofit organization dedicated to reshaping the perception of Latinos as part of the American social mainstream, shared a 2024 statistic saying “that Latinos have higher rates of new business ownership compared to any other racial or ethnic group with 0.60% of Latinos starting new businesses compared to 0.35% for overall U.S.”

“Latinas have continued to open businesses across the U.S. to not only bring new services and products to the market but also to successfully close the wage gap and create new job opportunities for others,” she said. “We are living in an era where Latinas are intentionally shaping the future of Latino finances within the many spaces that they increasingly control.”

About SHENIX®
SHENIX®, powered by FARO Advisory, is an innovative fintech company dedicated to providing educational resources and tools to empower Latinas in their financial journeys. With a deep understanding of the unique challenges faced by Latinas, SHENIX® is committed to equipping them with the knowledge and resources they need to make the best financial decisions for themselves and their communities. For more information, visit https://SHENIX.app/.

All Investment Advisory Services are provided by Centric Wealth Management, LLC d/b/a SHENIX®, an SEC Registered Investment Advisor. Registration with the SEC does not imply a certain level of skill or expertise. SHENIX® is affiliated with and controlled by FARO Advisory. SHENIX® and FARO Advisory are not affiliated with Centric Wealth Management, LLC. Additional information about Centric Wealth Management, LLC d/b/a SHENIX®, is available in its current disclosure documents, Form ADV Part 1A, Form ADV Part 2A Brochure, and Client Relationship Summary report which are accessible online via the SEC’s investment Adviser Public Disclosure (IAPD) database at http://www.adviserinfo.sec.gov, using SEC #801-63837. Centric Wealth Management, LLC does not offer or provide legal or tax advice. Please consult your attorney and/or tax advisor for such services.

Media Contact

Marie Lazzara, JJR Marketing, 630-400-3361, marie@jjrmarketing.com, https://jjrmarketing.com/

View original content to download multimedia:https://www.prweb.com/releases/chicago-based-fintech-app-shenix-celebrates-first-anniversary-on-latina-equal-pay-day-oct-3-platform-founder-describes-new-app-features-way-to-close-latina-wage-gap-302265249.html

SOURCE SHENIX

Continue Reading

Technology

Expanded Partnership Between Pearson and Degreed Helps Organizations Identify, Develop and Validate Future Skills for Business Transformation

Published

on

By

HOBOKEN, N.J., Oct. 2, 2024 /PRNewswire/ — Pearson (FTSE: PSON.L), the world’s lifelong learning company, and Degreed are expanding their partnership to help organizations future-proof their talent in the AI era. Together, they will enable enterprises and employees to adapt their workforce skills among evolving technologies and market dynamics, ensuring long-term business resilience.

The Degreed Skills dashboard will integrate Faethm by Pearson data sets, offering real-time insights into the most relevant skills across industries.  With this new capability, Degreed customers can compare their workforce’s skills to industry benchmarks, identify gaps, and prioritize key areas for upskilling.

This combined solution helps enterprises drive productivity and innovation through focused training programs that align with their strategic goals, ensuring they maintain a competitive edge in an evolving marketplace.

“AI is rapidly transforming the way we work, and in this shifting landscape one thing is clear: the future belongs to those who are prepared,” said Vishaal Gupta, President of Pearson’s Workforce Skills division. “Pearson’s partnership with Degreed helps customers identify, develop, and validate their employees’ skills to keep up with changing workforce needs, so they’re always equipped with the most relevant expertise, today and tomorrow.”

“We are thrilled to extend our partnership with Pearson to embed Faethm into the core Degreed platform. Every one of our clients is challenged to keep up with the pace of change. This new integration will provide L&D professionals with actionable, up-to-date insight into demand for workforce skills so they can deliver more personalized learning to their teams,” said Max Wessel, co-CEO of Degreed. “This builds upon Degreed’s innovations in skills, automation, and AI.  Today, clients don’t need to choose between scaling learning programs to reach more employees and personalizing those programs so they can drive workforce outcomes with pinpoint precision. They can have both.”

Today’s announcement is part of Pearson’s ongoing strategic commitment to the enterprise and workforce skills market. It builds on the existing partnership between Degreed and Pearson, which recognizes key achievements and validates high-value skills through Pearson’s digital credential platform, Credly.  These credentials are awarded based on the completion of learning pathways within Degreed’s platform, which may include assessment results, course completions and other predefined criteria.

Credly and Faethm are part of Pearson’s Workforce Skills division, which is focused on preparing individuals and organizations for the future of work. Pearson’s enterprise focused businesses help people build high demand skills and provide organizations with solutions for strategic workforce planning, digital credentialling, role assessments, and GED education.

About Pearson

At Pearson, our purpose is simple: to help people realize the life they imagine through learning. We believe that every learning opportunity is a chance for a personal breakthrough. That’s why our c. 18,000 Pearson employees are committed to creating vibrant and enriching learning experiences designed for real-life impact. We are the world’s lifelong learning company, serving customers in nearly 200 countries with digital content, assessments, qualifications, and data. For us, learning isn’t just what we do. It’s who we are. Visit us at pearsonplc.com.

About Degreed

Degreed is the enterprise learning company, offering the world’s leading experience platform to drive skill driven development. Degreed enables organizations to collect, understand, and build skills to develop a workforce that’s ready for anything. To learn more about Degreed, visit www.degreed.com

Jaclyn Pullen
Jpullen@panblastpr.com 

Sara Bartlett
sara.bartlett@pearson.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/expanded-partnership-between-pearson-and-degreed-helps-organizations-identify-develop-and-validate-future-skills-for-business-transformation-302265327.html

SOURCE Pearson

Continue Reading

Technology

Visionet Ventures launches Reteta, an AI-powered solution to automate medical documentation and enhance patient care delivery

Published

on

By

CRANBURY, N.J., Oct. 2, 2024 /PRNewswire/ — Visionet Ventures is proud to announce the launch of Reteta, a transformative clinical care application that leverages Ambient AI to streamline medical documentation and enhance the clinician and patient experience. With over two years of development effort, backed by $2 million in seed funding, Reteta is designed to alleviate the heavy administrative burden faced by healthcare professionals, allowing them to devote more time to patient care.

Visionet Ventures launches Reteta, an AI-powered solution to automate medical documentation and enhance patient care

At the core of Reteta is its ability to automatically generate SOAP (Subjective, Objective, Assessment, Plan) notes, after visit summaries and referral letters to other specialties. It also helps clinicians get up to speed with patients by writing comprehensive pre-charting, which significantly reduces documentation time to just two minutes on average.

Covering over 15 specialties, Reteta’s AI-powered scribing tool, Reteta sKribe, converts patient-physician interactions into comprehensive medical notes that clinicians can quickly review and sign, enabling up to two hours of daily time savings. Its ambient dictation and speech recognition ensure that 80% of notes are accepted without edits, reducing burnout and enhancing patient interactions. Further enhancing its impact, Reteta Bcoder automates medical coding with 90% accuracy, offering a 70% productivity gain by reducing coding errors and claim denials.

Integrating smoothly with Electronic Health Record (EHR) systems and Revenue Cycle Management (RCM) workflows, Reteta delivers significant efficiency improvements without disrupting existing infrastructure.

“Reteta is more than just automating documentation and processes— its about bringing the joy of medicine back to healthcare professionals and pushing the envelope of possibilities with AI in healthcare,” said Arshad Masood, Managing Director of Visionet Ventures. “With Ambient AI handling documentation, we’re significantly reducing the manual work that leads to burnout, automating the most basic and redundant tasks healthcare providers face daily. Plus, our deep expertise in integration ensures a smooth adoption, seamlessly fitting into existing workflows while enhancing accuracy and efficiency in clinical settings.”

Reteta’s commitment to security is demonstrated through its end-to-end encryption and HIPAA-compliant framework. Sensitive patient information is safeguarded at every stage, ensuring that healthcare providers can confidently use Reteta to enhance their operational efficiency while maintaining high standards of data protection. As a result, Reteta empowers hospitals, physicians, and telehealth providers with a comprehensive AI-driven solution that addresses some of the most critical challenges in healthcare today.

About Visionet Ventures
Visionet Ventures, the innovation and incubation arm of Visionet Systems Inc., develops and launches cutting-edge products that harness AI and emerging technologies to address real-world challenges. By creating smart, data-driven solutions tailored to specific business needs, Visionet Ventures drives industry transformation and technological advancement. Learn more at www.visionetventures.com.

About Reteta
Reteta is an AI-powered clinical care platform streamlining and automating medical documentation and coding, enabling better care delivery. With its singular focus on automating SOAP note generation and medical coding, Reteta ensures frictionless adoption, reduces clinician burnout, increases efficiency, and empowers healthcare professionals to concentrate on delivering quality patient care. Learn more at www.reteta.com.

CONTACT: pr@visionet.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/visionet-ventures-launches-reteta-an-ai-powered-solution-to-automate-medical-documentation-and-enhance-patient-care-delivery-302265718.html

SOURCE Visionet Ventures

Continue Reading

Trending